Publication:
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.

No Thumbnail Available

Date

2020-03-22

Authors

Daudén, Esteban
Carretero, Gregorio
Rivera, Raquel
Ferrándiz, Carlos
Llamas-Velasco, Mar
de la Cueva, Pablo
Belinchón, Isabel
Gómez-García, Francisco José
Herrera-Acosta, Enrique
Ruiz-Genao, Diana Patricia

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort. Our study included 2845 patients (8954 treatment cycles; 9642 patient-years). Ustekinumab and secukinumab had the lowest rate of adverse events for several of the system organ classes, with a statistically significant decreased rate ratio (IRR of Observational study, drug allocation not randomized, depletion of susceptibles, and prescribed doses not registered. Our data provide comparative safety information in the real-life setting that could help clinicians selecting between available products.

Description

MeSH Terms

Adult
Aged
Biological Therapy
Cohort Studies
Female
Humans
Male
Middle Aged
Psoriasis
Registries
Spain
Time Factors

DeCS Terms

CIE Terms

Keywords

adverse effects, anti-TNF, anti-inflammatory agents, biologic agents, immunosuppressive agents, long-term follow-up, pharmacovigilance, prospective cohort, psoriasis/drug therapy, registries, safety

Citation